Janney Montgomery Scott
NBIX icon

Janney Montgomery Scott’s Neurocrine Biosciences NBIX Stock Holding History

Janney Montgomery Scott’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.42M Sell
10,764
-272
-2% -$36.1K ﹤0.01% 1459
2025
Q4 		$1.56M Sell
11,036
-1,779
-14% -$258K ﹤0.01% 1471
2025
Q3 		$1.8M Sell
12,815
-883
-6% -$120K ﹤0.01% 1366
2025
Q2 		$1.72M Buy
13,698
+830
+6% +$95.2K ﹤0.01% 1285
2025
Q1 		$1.42M Sell
12,868
-4,677
-27% -$592K ﹤0.01% 1326
2024
Q4 		$2.4M Buy
17,545
+1,150
+7% +$142K 0.01% 1075
2024
Q3 		$1.89M Sell
16,395
-413
-2% -$56.6K 0.01% 1165
2024
Q2 		$2.31M Buy
16,808
+7,901
+89% +$1.08M 0.01% 1037
2024
Q1 		$1.23M Buy
8,907
+270
+3% +$36.9K ﹤0.01% 1414
2023
Q4 		$1.14M Buy
8,637
+4,030
+87% +$464K ﹤0.01% 1376
2023
Q3 		$518K Buy
4,607
+348
+8% +$36.6K ﹤0.01% 1744
2023
Q2 		$402K Sell
4,259
-44,204
-91% -$4.32M ﹤0.01% 2028
2023
Q1 		$4.91M Buy
48,463
+3,460
+8% +$360K 0.02% 647
2022
Q4 		$5.38M Buy
45,003
+41,119
+1,059% +$4.82M 0.02% 648
2022
Q3 		$413K Buy
3,884
+1,675
+76% +$170K ﹤0.01% 1810
2022
Q2 		$215K Sell
2,209
-1,062
-32% -$98K ﹤0.01% 2099
2022
Q1 		$307K Sell
3,271
-166
-5% -$14.1K ﹤0.01% 1873
2021
Q4 		$293K Sell
3,437
-12,334
-78% -$1.13M ﹤0.01% 2013
2021
Q3 		$1.51M Buy
15,771
+799
+5% +$75.5K 0.01% 1080
2021
Q2 		$1.46M Sell
14,972
-2,784
-16% -$267K 0.01% 1090
2021
Q1 		$1.73M Buy
17,756
+12,373
+230% +$1.3M 0.01% 954
2020
Q4 		$516K Sell
5,383
-7,247
-57% -$700K ﹤0.01% 1552
2020
Q3 		$1.22M Buy
12,630
+742
+6% +$85.8K 0.01% 1008
2020
Q2 		$1.45M Buy
11,888
+172
+1% +$19K 0.01% 881
2020
Q1 		$1.01M Buy
11,716
+1,198
+11% +$117K 0.01% 927
2019
Q4 		$1.13M Sell
10,518
-653
-6% -$68.4K 0.01% 1019
2019
Q3 		$1.01M Buy
11,171
+309
+3% +$28.9K 0.01% 1036
2019
Q2 		$917K Buy
10,862
+1,545
+17% +$127K 0.01% 1097
2019
Q1 		$821K Buy
+9,317
New +$779K 0.01% 1128
2016
Q4 		– Sell
-8,924
Closed -$452K – 1711
2016
Q3 		$452K Buy
+8,924
New +$444K 0.01% 1013
2016
Q2 		– Sell
-8,924
Closed -$353K – 998
2016
Q1 		$353K Sell
8,924
-1,096
-11% -$43.5K 0.01% 897
2015
Q4 		$567K Hold
10,020
– – 0.01% 765
2015
Q3 		$399K Buy
10,020
+596
+6% +$28.8K 0.01% 936
2015
Q2 		$450K Buy
9,424
+2,023
+27% +$85.8K 0.01% 1239
2015
Q1 		$294K Buy
+7,401
New +$265K 0.01% 1783

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janney Montgomery Scott's NBIX Position: Q1 2026 in Review

Janney Montgomery Scott reduced its Neurocrine Biosciences (NBIX) stake by 2.5% in Q1 2026, selling an estimated $36.1K and leaving 10,764 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #1459.

Janney Montgomery Scott first reported a position in NBIX in Q1 2015 and has held it in 35 quarters since. The position peaked at $5.38M in Q4 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Janney Montgomery Scott held 10,764 shares of Neurocrine Biosciences worth $1.42M as of Q1 2026.
  • Janney Montgomery Scott sold 272 Neurocrine Biosciences shares in Q1 2026, an estimated $36.1K.
  • Neurocrine Biosciences made up ﹤0.01% of Janney Montgomery Scott's portfolio in Q1 2026, its #1459 holding.
  • Janney Montgomery Scott first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 35 quarters since.
  • Janney Montgomery Scott's Neurocrine Biosciences position peaked at $5.38M in Q4 2022.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Janney Montgomery Scott's 13F filing for Q1 2026, filed 22 Apr 2026.